Hexarelin Acetate
A potent GHRP with strong cardioprotective signalling in pre-clinical work.
How it works
Activates GHSR-1a and the CD36 receptor; the latter underlies its cardiac effects independent of GH release.
Reported benefits
- Highest peak GH release among GHRPs
- Cardioprotective signalling via CD36 in animal models
Dosage & administration
Research range: 100 mcg subcutaneously 1-3x daily.
Dosing information is summarised from published clinical and pre-clinical literature for research purposes only and does not constitute medical advice.
Clinical & pre-clinical evidence
Hexarelin in cardiac ischemia
Cardiovascular Research · 1999
Reduced infarct size in rat ischemia-reperfusion models.
Safety & warnings
- Cortisol and prolactin elevation possible at higher doses
- Pituitary desensitisation with continuous use — cycle
For research use. Consult a licensed clinician before any human application. Not for use in pregnancy, lactation, or active malignancy without specialist supervision.
Available presentations
5 mg
HX5
Box of 10 · $261
Single vial · $522
Related guides
BPC 157
A pentadecapeptide derived from human gastric juice with broad regenerative effects in pre-clinical models.
TB500 (Thymosin B4 Acetate)
A synthetic fragment of thymosin β-4 that promotes cell migration, angiogenesis, and tissue repair.
BPC + TB Blend
Combined BPC 157 and TB500 blend used in recovery protocols to overlap angiogenic and cytoskeletal effects.